Clinical Trials Sponsored by Beta-Stim Ltd.

Total 146 results

Beta-Stim Ltd.
Meditrial Europe Ltd.

Completed

Balance System Study in Type 2 Diabetic Patients

Obesity | Type 2 Diabetes

Germany
Stem Cell Medicine Ltd.

Withdrawn

Study to Assess the Safety and Efficacy of an IT Administration of SCM-010 in SPMS

Secondary Progressive Multiple Sclerosis (SPMS)

Israel
Beta Pharma (Suzhou) Co., Ltd.

Recruiting

A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

Advanced Solid Tumor | HR+/HER2- Breast Cancer

China
Kang Stem Biotech Co., Ltd.

Active, not recruiting

Evalution the Safety and Efficacy in Atopic Dermatitis Patients

Atopic Dermatitis

Korea, Republic of
Kang Stem Biotech Co., Ltd.

Unknown

Safety of FURESTEM-CD Inj. in Patients With Moderate to Severe Plaque-type Psoriasis

Psoriasis

Korea, Republic of
Kang Stem Biotech Co., Ltd.

Unknown

Long-term Safety and Efficacy of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease(CD)

Crohn's Disease

Korea, Republic of
Kang Stem Biotech Co., Ltd.

Not yet recruiting

Evaluate Safety and Explore Efficacy of FURESTEM-OA Kit Inj. in Patients With Knee Osteoarthritis

Knee Osteoarthritis
Kang Stem Biotech Co., Ltd.

Recruiting

Safety and Efficacy of FURESTEM-AD Inj. for Moderate to Severe Atopic Dermatitis (AD) (smart(FURIN))

Dermatitis, Atopic

Korea, Republic of
Kang Stem Biotech Co., Ltd.

Not yet recruiting

Long-term Follow-up Study to Evaluate the Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD Inj

Atopic Dermatitis

Korea, Republic of
Kang Stem Biotech Co., Ltd.

Recruiting

Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD Inj. for Moderate to Severe Chronic Atopic Dermatitis

Atopic Dermatitis

Korea, Republic of
Kang Stem Biotech Co., Ltd.

Recruiting

Administration for Placebo Group and Evalution the Safety and Efficacy in Atopic Dermatitis Patients

Atopic Dermatitis

Korea, Republic of
Kang Stem Biotech Co., Ltd.

Not yet recruiting

Long-Term Follow-up Study of Subjects With Knee Osteoarthritis Who Had Administered FURESTEM-OA Kit Inj. in K0701 Study

Knee Osteoarthritis
Kang Stem Biotech Co., Ltd.

Recruiting

Long-term Observational Study to Evaluation the Safety of FURESTEM-RA Inj(K0202)

Rheumatoid Arthritis

Korea, Republic of
Kang Stem Biotech Co., Ltd.

Completed

Safety and Efficacy of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis

Rheumatoid Arthritis

Korea, Republic of
Kang Stem Biotech Co., Ltd.

Completed

Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderate to Severe Chronic Atopic Dermatitis(AD)

Atopic Dermatitis

Korea, Republic of
Kang Stem Biotech Co., Ltd.

Unknown

Long-term Observational Study to Evalution the Safety and Efficacy of FURESTEM-AD Inj.

Atopic Dermatitis

Korea, Republic of
Kang Stem Biotech Co., Ltd.

Unknown

Long-term Observational Study to Evaluation the Safety of FURESTEM-RA Inj

Rheumatoid Arthritis

Korea, Republic of
Kang Stem Biotech Co., Ltd.

Unknown

Safety and Efficacy of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease(CD)

Crohn's Disease

Korea, Republic of
Kang Stem Biotech Co., Ltd.

Completed

Safety of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis(RA) (RA)

Rheumatoid Arthritis

Korea, Republic of
Kang Stem Biotech Co., Ltd.

Completed

Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis (AD)

Atopic Dermatitis

Korea, Republic of
Betta Pharmaceuticals Co., Ltd.

Not yet recruiting

Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients

Colorectal Cancer | Pancreatic Cancer | Solid Tumor | Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

A Phase 1 Study of BPI-28592 in Subjects With Advanced Solid Tumors

Metastasis, Neoplasm

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy (SMART)

Non Small Cell Lung Cancer | Brain Metastases

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

A Phase I Study of BPI-16350 in Patients With Advanced Solid Tumor

Advanced Solid Cancer

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer

EGF-R Positive Non-Small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC

Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Completed

Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK

Solid Tumor | Non-Small Cell Lung Cancer Metastatic

China
Betta Pharmaceuticals Co., Ltd.

Active, not recruiting

A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer

Breast Cancer

China
Betta Pharmaceuticals Co., Ltd.

Active, not recruiting

The Absorption, Metabolism and Excretion of [14C]D-0316 in Human

Advanced or Metastatic Non-small Cell Lung

China
Betta Pharmaceuticals Co., Ltd.

Completed

Safety, Tolerability and Pharmacokinetic Profile of BPI-15086 in EGFR T790M Mutation-positive NSCLC Patients

Non-Small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Completed

Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH

Esophageal Carcinoma | Adenocarcinoma of the Gastroesophageal Junction

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation

Non-Small Cell Lung Cancer | Brain Metastases
Betta Pharmaceuticals Co., Ltd.

Unknown

High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation (INCREASE)

NSCLC

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib Treatment

Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic Insufficiency

Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases

Non-small-cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Unknown

High Dose Versus Routine Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With Stable Disease

Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Suspended

Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy

Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI

Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC

Adenocarcinoma | EGFR Positive Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Completed

Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients (ICOGEN)

Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

BPB-101 in Subjects With Metastatic or Locally Advanced Solid Tumors

Solid Tumor

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

A Study of BPI-460372 in Advanced Solid Tumor Patients

Advanced Solid Tumor

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BPI-21668

Advanced Solid Tumor

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors

Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors

Metastatic Cancer | Malignant Neoplasms

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

Head and Neck Cancer | Colorectal Cancer | Non-Small Cell Lung Cancer | Solid Tumor

China
Betta Pharmaceuticals Co., Ltd.

Completed

A Food-Effect Study of BPI-16350 in Healthy Subjects

Healthy

China
Betta Pharmaceuticals Co., Ltd.

Active, not recruiting

Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation (EVIDENCE)

Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Unknown

High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases

Non-small Cell Lung Cancer | Brain Metastases

China

3

Subscribe